{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-025827","form_type":"8-K","ticker":"COCH","cik":"0001840877","company_name":"Envoy Medical, Inc.","filed_at":"2025-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.222937+00:00","generated_at":"2026-05-24T02:21:36.777189+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Envoy Medical FY2024 revenue down $91K; clinical trial enrollment advances","bullets":["Net revenues decreased $91K YoY; cash and equivalents were $5.5M as of Dec 31, 2024.","R&D expenses increased $1.2M driven by headcount for Acclaim cochlear implant pivotal study.","FDA approved pivotal trial; 6 of 10 planned first-stage participants enrolled and implanted.","New CPT codes for fully implanted middle ear implants effective July 2025; Hearing Device Coverage Clarification Act reintroduced.","G&A expenses down $438K reflecting lower professional fees post-business combination."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-025827","json":"https://secwatch.observer/filing/0001213900-25-025827.json","markdown":"https://secwatch.observer/filing/0001213900-25-025827.md","text":"https://secwatch.observer/filing/0001213900-25-025827.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840877/000121390025025827/0001213900-25-025827-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840877/000121390025025827/ea0236135-8k_envoy.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T02:21:36.777189+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}